Werewolf Therapeutics | SC 13D/A:超过5%持股股东披露文件(修正)-RA Capital Management, L.P.(14.2%),Peter Kolchinsky(14.2%)等
Werewolf Therapeutics | 10-Q:季度报表
Werewolf Therapeutics | 8-K:Werewolf Therapeutics公布2024年第一季度财务业绩并提供业务最新情况
Werewolf Therapeutics | ARS:年度报告
Werewolf Therapeutics | DEFA14A:其他
Werewolf Therapeutics | DEF 14A:股东委托书决议
Werewolf Therapeutics | S-8:员工福利计划证券登记
Werewolf Therapeutics | 10-K:年度报表
Werewolf Therapeutics | 8-K:Werewolf Therapeutics公布2023年第四季度和全年财务业绩并提供业务最新情况
Werewolf Therapeutics | SC 13D/A:超过5%持股股东披露文件(修正)-RA Capital Management, L.P.(15.2%),Peter Kolchinsky(15.2%)等
Werewolf Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-PFM Health Sciences, LP(9.6%),PFM Health Sciences GP, LLC(9.6%)等
Werewolf Therapeutics | SC 13G:超过5%持股股东披露文件-BANK OF AMERICA CORPORATION(5.8%)
Werewolf Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-Rubric Capital Management LP(5.35%),David Rosen(5.35%)
Werewolf Therapeutics | 8-K:重大事件
Werewolf Therapeutics | 424B5:募资说明书
Werewolf Therapeutics | 8-K:重大事件
Werewolf Therapeutics | 4:持股变动声明-董事 Atkins Michael B.
Werewolf Therapeutics | 3:首次持股声明-董事 Atkins Michael B.
Werewolf Therapeutics | 8-K:重大事件
Werewolf Therapeutics | 4:持股变动声明-高管 Trost Timothy W.
暂无数据